In successful RTK targeted therapy paradigms, like EGFR inhibitors in EGFR-mutant NSCLC, sensitivity is conferred because EGFR inhibitors lead to simultaneous downregulation of PI3K and MEK pathways; restoration of either pathway is sufficient to confer resistance (13, 15). Here, EGFR is linked to non-small cell lung carcinoma.